isomorphic Labs

Extracted Attributes

• Name

  Isomorphic Labs

• Industry

  Drug Discovery, Biotechnology Research

• President

  Colin Murdoch

• Headquarters

  London, UK

• Founding Date

  2021-02-24

• Funding Raised

  600 million USD

• Parent Company

  Alphabet Inc.

• Core Technology

  Artificial intelligence for drug discovery, leveraging AlphaFold and AlphaFold 3

• Founder and CEO

  Demis Hassabis

• Office Location

  Lausanne, Switzerland

• Announcement Date

  2021-11-04

• Number of Employees

  51-200

Timeline

• Isomorphic Labs was incorporated. (Source: Wikipedia)

  2021-02-24

• Isomorphic Labs was publicly announced as a new Alphabet company and spin-off from DeepMind. (Source: Wikipedia)

  2021-11-04

• Isomorphic Labs announced the opening of its second office location in Lausanne, Switzerland. (Source: Wikipedia)

  2022-12

• Isomorphic Labs partnered with Novartis AG and Eli Lilly and Company for AI-driven drug discovery and research. (Source: summary, Wikipedia)

  2024-01

• Google DeepMind and Isomorphic Labs announced the release of AlphaFold 3, a new AI foundation model for predicting protein folding and interactions with drug molecules. (Source: summary, Wikipedia)

  2024-05

• Preliminary results from CASP16 indicated that AlphaFold 3-based models did not significantly outperform older methods for predicting protein-ligand interactions in specific tests. (Source: summary, Wikipedia)

  2024-11

• Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital. (Source: summary, Wikipedia)

  2025-04

Isomorphic Labs

Isomorphic Labs Limited is a London-based company which uses artificial intelligence for drug discovery. Isomorphic Labs was founded by Demis Hassabis, who is the CEO. The company was incorporated on February 24, 2021 and announced on November 4, 2021. It was established under Alphabet Inc. as a spin-off from its AI research lab DeepMind, of which Hassabis is also founder and CEO. The company draws upon DeepMind's AlphaFold technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery. In December 2022, Isomorphic Labs announced its second office location in Lausanne, Switzerland. In January 2024, Isomorphic Labs partnered with Novartis AG and Eli Lilly and Company to work together on AI drug discovery and research. In May 2024, Google DeepMind and Isomorphic Labs announced the release of AlphaFold 3, an artificial intelligence and foundation model platform. Available for free on the AlphaFold server for non-commercial research, the platform was developed by training it with nearly 100,000 known proteins. AlphaFold 3 can predict how proteins fold and the interactions with molecules typically found in drugs such as ligands or antibodies, which is expected to significantly accelerate drug discovery. In November 2024, preliminary results of CASP16 showed AlphaFold 3-based models did not significantly outperform older methods for predicting protein-ligand interactions. The top performing models in the CASP16 Pose Prediction for Pharma Targets section were ClusPro and CoDock utilizing AlphaFold 2 based predictions, human visual inspection, and manual adjustments. Despite these results, in April 2025 Isomorphic Labs raised $600 Million in its first ever external funding round, led by Thrive Capital.

Web Search Results

• Isomorphic Labs | LinkedIn

  Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that [...] discovery. [Likes: 677, Comments: 58]; Isomorphic Labs (1w): Heading to ICML and interested in finding out more about Isomorphic Labs ? Register to connect with our team at ICML between 13-19 July: bit.ly/44ug6t4 Be sure to catch a talk by Jack L. and Benedek Rozemberczki - Isomorphic Labs: Towards a System for Rational Drug Design with AI We’re currently hiring for a series of ML roles, focusing on AI for Drug Discovery, to support the rapid growth of our best-in-class AI models. We're looking [...] # Isomorphic Labs We are reimagining the entire drug discovery process from first principles with an AI-first approach. Biotechnology Research • London • 53,595 followers • 51-200 employees

• Using our state-of-the-art AI models to power drug design

  The whole process of bringing new medicines to patients is very long and complex and success isn’t always guaranteed. Isomorphic Labs, however, is taking a unique approach in employing machine learning - we’re working on building models from first principles to answer the fundamental questions that can change the way we design drugs. Ultimately our goal is to make the process much more efficient, successful, and safer, leading to design drugs for challenging disease areas and that can result in

• Our Tech - Isomorphic Labs

  Our heritage of breakthroughs in this space is unique - we were launched from DeepMind and many of our team contributed to the creation of the groundbreaking AlphaFold system. Now, the Isomorphic Labs team has built and developed even more advanced AI models that together form a unified state-of-the-art drug design engine that will transform how we design new drugs and ultimately change the way medicine will help and heal people. [...] At Isomorphic Labs, we’re harnessing AI’s extraordinary power to reimagine and advance the drug design process from first principles. The technology we have developed allows our researchers to explore a new chemical landscape, enabling them to take on historically challenging targets with increased pace and accuracy. ‍ [...] 2 a--up none 0 a--up none COLIN MURDOCH, PRESIDENT 0 a--up none ### “The strength of Isomorphic Labs is not only found in its technological capabilities, or the compute power and resources we have access to. It’s also found within our team - an interdisciplinary powerhouse turning the full force of its expertise to some of the most devastating diseases we face.” 1 a--up none 0 a--up none ## Isomorphic Labs’ unified drug design engine 0 a--up none 1 a--up none 2 a--up

• Isomorphic Labs

  Isomorphic Labs was founded in 2021, with a mission to transform drug discovery with the power of artificial intelligence. Led by AI pioneer Sir Demis Hassabis, our founding was built on the Nobel-winning AI breakthrough, AlphaFold. Together with Google DeepMind, we developed and released AlphaFold 3 in May 2024, a revolutionary AI model that can predict the structure and interactions of all of life’s molecules with unprecedented accuracy. Our interdisciplinary team of drug discovery experts [...] and machine learning specialists has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Our breakthrough technology is creating a broad and ambitious drug design portfolio of partnered and wholly-owned internal programs.

• Isomorphic Labs: Reimagining Drug Discovery Process with AI

  Isomorphic Labs was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed. [...] # Solve all disease 0 a--up none We’re entering a new era of drug discovery — one where frontier AI can unlock deeper scientific insights, faster breakthroughs, and life-changing medicines. At Isomorphic Labs, we’re building that future. 2 a--up a--h-150-100 1 a--up none a--up 3 2 1 0 a--up none 0 a--up none